Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?

H. McManus, Pck Li, D. Nolan, M. Bloch, S. Kiertiburanakul, JunYong Choi, B. Mulhall, K. Petoumenos, J. Zhou, M. Law, B. J. Brew, E. Wright

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: The aim of the study was to determine whether combination antiretroviral therapy (cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is associated with increased survival benefit compared with non-neurocART. Methods: Prospective data were examined for HIV-positive patients in the Asia Pacific HIV Observational Database who had commenced cART. CPE rank was calculated using the 2010 rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more. Survival was analysed using Cox proportional hazards models with covariates updated at changes in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen. Sensitivity analyses were conducted to examine the robustness of analysis assumptions. Results: Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use was 0.89 (P=0.35) when data were stratified by cohort and adjusted for age, mode of HIV exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite endpoint of AIDS-defining illness or death (HR=0.93; P=0.61), baseline regimen as neurocART (HR=0.95; P=0.69), CPE category (P=0.71) and prior neurocART duration (P=0.16). No association between CD4 cell count and neurocART use was observed (P=0.52). Conclusions: Our findings do not show a significant overall survival benefit associated with neurocART compared with cART. The potential benefit associated with neurocART in terms of prevention of neurocognitive impairment did not translate into an improvement in overall survival in this population. These findings were limited by the low incidence of associated mortality. Further studies and more extensive data are needed to address these limitations.

Original languageEnglish
Pages (from-to)610-619
Number of pages10
JournalHIV Medicine
Volume12
Issue number10
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Central Nervous System
HIV
Survival
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
Therapeutics
Coinfection
Proportional Hazards Models
Hepatitis B virus
Databases
Mortality
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

McManus, H. ; Li, Pck ; Nolan, D. ; Bloch, M. ; Kiertiburanakul, S. ; Choi, JunYong ; Mulhall, B. ; Petoumenos, K. ; Zhou, J. ; Law, M. ; Brew, B. J. ; Wright, E. / Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?. In: HIV Medicine. 2011 ; Vol. 12, No. 10. pp. 610-619.
@article{90673208a5224a82a980d93afb9fbe3d,
title = "Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?",
abstract = "Objectives: The aim of the study was to determine whether combination antiretroviral therapy (cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is associated with increased survival benefit compared with non-neurocART. Methods: Prospective data were examined for HIV-positive patients in the Asia Pacific HIV Observational Database who had commenced cART. CPE rank was calculated using the 2010 rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more. Survival was analysed using Cox proportional hazards models with covariates updated at changes in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen. Sensitivity analyses were conducted to examine the robustness of analysis assumptions. Results: Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use was 0.89 (P=0.35) when data were stratified by cohort and adjusted for age, mode of HIV exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite endpoint of AIDS-defining illness or death (HR=0.93; P=0.61), baseline regimen as neurocART (HR=0.95; P=0.69), CPE category (P=0.71) and prior neurocART duration (P=0.16). No association between CD4 cell count and neurocART use was observed (P=0.52). Conclusions: Our findings do not show a significant overall survival benefit associated with neurocART compared with cART. The potential benefit associated with neurocART in terms of prevention of neurocognitive impairment did not translate into an improvement in overall survival in this population. These findings were limited by the low incidence of associated mortality. Further studies and more extensive data are needed to address these limitations.",
author = "H. McManus and Pck Li and D. Nolan and M. Bloch and S. Kiertiburanakul and JunYong Choi and B. Mulhall and K. Petoumenos and J. Zhou and M. Law and Brew, {B. J.} and E. Wright",
year = "2011",
month = "11",
day = "1",
doi = "10.1111/j.1468-1293.2011.00938.x",
language = "English",
volume = "12",
pages = "610--619",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "10",

}

McManus, H, Li, P, Nolan, D, Bloch, M, Kiertiburanakul, S, Choi, J, Mulhall, B, Petoumenos, K, Zhou, J, Law, M, Brew, BJ & Wright, E 2011, 'Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?', HIV Medicine, vol. 12, no. 10, pp. 610-619. https://doi.org/10.1111/j.1468-1293.2011.00938.x

Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults? / McManus, H.; Li, Pck; Nolan, D.; Bloch, M.; Kiertiburanakul, S.; Choi, JunYong; Mulhall, B.; Petoumenos, K.; Zhou, J.; Law, M.; Brew, B. J.; Wright, E.

In: HIV Medicine, Vol. 12, No. 10, 01.11.2011, p. 610-619.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?

AU - McManus, H.

AU - Li, Pck

AU - Nolan, D.

AU - Bloch, M.

AU - Kiertiburanakul, S.

AU - Choi, JunYong

AU - Mulhall, B.

AU - Petoumenos, K.

AU - Zhou, J.

AU - Law, M.

AU - Brew, B. J.

AU - Wright, E.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objectives: The aim of the study was to determine whether combination antiretroviral therapy (cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is associated with increased survival benefit compared with non-neurocART. Methods: Prospective data were examined for HIV-positive patients in the Asia Pacific HIV Observational Database who had commenced cART. CPE rank was calculated using the 2010 rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more. Survival was analysed using Cox proportional hazards models with covariates updated at changes in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen. Sensitivity analyses were conducted to examine the robustness of analysis assumptions. Results: Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use was 0.89 (P=0.35) when data were stratified by cohort and adjusted for age, mode of HIV exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite endpoint of AIDS-defining illness or death (HR=0.93; P=0.61), baseline regimen as neurocART (HR=0.95; P=0.69), CPE category (P=0.71) and prior neurocART duration (P=0.16). No association between CD4 cell count and neurocART use was observed (P=0.52). Conclusions: Our findings do not show a significant overall survival benefit associated with neurocART compared with cART. The potential benefit associated with neurocART in terms of prevention of neurocognitive impairment did not translate into an improvement in overall survival in this population. These findings were limited by the low incidence of associated mortality. Further studies and more extensive data are needed to address these limitations.

AB - Objectives: The aim of the study was to determine whether combination antiretroviral therapy (cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is associated with increased survival benefit compared with non-neurocART. Methods: Prospective data were examined for HIV-positive patients in the Asia Pacific HIV Observational Database who had commenced cART. CPE rank was calculated using the 2010 rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more. Survival was analysed using Cox proportional hazards models with covariates updated at changes in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen. Sensitivity analyses were conducted to examine the robustness of analysis assumptions. Results: Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use was 0.89 (P=0.35) when data were stratified by cohort and adjusted for age, mode of HIV exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite endpoint of AIDS-defining illness or death (HR=0.93; P=0.61), baseline regimen as neurocART (HR=0.95; P=0.69), CPE category (P=0.71) and prior neurocART duration (P=0.16). No association between CD4 cell count and neurocART use was observed (P=0.52). Conclusions: Our findings do not show a significant overall survival benefit associated with neurocART compared with cART. The potential benefit associated with neurocART in terms of prevention of neurocognitive impairment did not translate into an improvement in overall survival in this population. These findings were limited by the low incidence of associated mortality. Further studies and more extensive data are needed to address these limitations.

UR - http://www.scopus.com/inward/record.url?scp=80054840297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054840297&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2011.00938.x

DO - 10.1111/j.1468-1293.2011.00938.x

M3 - Article

VL - 12

SP - 610

EP - 619

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 10

ER -